Skip to main contentSkip to institutions
FinancingReport #9

Healthcare Financing & Insurance

China Healthcare Guide Research
Updated:

Executive Summary

China's healthcare financing has evolved with government health expenditure reaching 7.2% of GDP in 2024. Volume-based procurement programs have generated over 500 billion yuan in annual savings while maintaining 95%+ population coverage through the multi-tiered UEBMI and URRBMI insurance systems.

Key Statistics

7.2%

Health Expenditure/GDP

Source: 2024

500B+ yuan

VBP Annual Savings

Source: Since inception

95%+

Insurance Coverage

Source: Population

Annual

NRDL Negotiations

Source: Drug pricing

Key Findings

  • 1Government health expenditure reached 7.2% of GDP in 2024
  • 2Volume-based procurement generating 500B+ yuan annual savings
  • 3Medical insurance funds maintaining financial sustainability
  • 4DRG/DIP payment reforms expanding nationwide
  • 5Commercial health insurance growing as supplement

Healthcare Expenditure

Government Investment

  • Health expenditure reached 7.2% of GDP in 2024
  • Continued increase from previous years
  • Commitment to universal coverage expansion

Expenditure Categories

  • Public health services
  • Hospital infrastructure
  • Medical insurance subsidies
  • Drug procurement programs

Medical Insurance System

Multi-Tiered Structure

UEBMI (Urban Employees)

  • Employer and employee contributions
  • Higher reimbursement rates (75-90%)
  • Medical savings accounts

URRBMI (Urban-Rural Residents)

  • Government subsidies + individual contributions
  • Moderate reimbursement rates (60-80%)
  • Basic coverage guarantee

Coverage Achievement

  • 95%+ population covered by basic insurance
  • Remaining gaps being addressed
  • Supplementary insurance options available

Payment Reforms

DRG/DIP Systems

Diagnosis-Related Group and Diagnosis-Intervention Packet payment reforms:

  • Moving from fee-for-service
  • Cost control incentives
  • Quality measurement integration
  • Nationwide expansion ongoing

Volume-Based Procurement (VBP)

Annual savings exceeding 500 billion yuan:

  • Centralized drug purchasing
  • Price reductions of 50-70%
  • Quality standards maintained
  • Generic drug utilization increased

Drug Pricing

National Reimbursement Drug List (NRDL)

  • Annual negotiation rounds
  • Innovative drugs included
  • Average price cuts of 60%+
  • Access expansion balanced with sustainability

Commercial Insurance Growth

  • Supplementary coverage expansion
  • Critical illness products
  • International healthcare coverage
  • Integration with basic insurance

Financial Sustainability

Challenges

  • Aging population pressures
  • Rising healthcare costs
  • New treatment technologies
  • Chronic disease burden

Solutions

  • Payment reform implementation
  • Procurement efficiency
  • Prevention emphasis
  • Technology adoption

Data Sources & References

  • 1National Healthcare Security Administration
  • 2Ministry of Finance
  • 3China Banking and Insurance Regulatory Commission

Data compiled from official government sources, peer-reviewed research, and industry reports. Last updated: February 17, 2026

Last updated: